TreatmentUpdate57, Vol. 7, No. 3 - March 1995
Sean Hosein

In this study researchers focused on the effect of the immunogen on CMI. Subjects in this were symptom-free, had at least a minimal level of CMI and at least 600 CD4+ cells. Researchers enrolled 46 men and 2 women, and divided them up at random and placed subjects into 5 groups, each receiving a different dose (50, 100, 200 or 400 mcg (micrograms) of the vaccine or just IFA. Subjects received at least 1 injection of the vaccine or IFA. Technicians then tested subjects regularly for CMI. If the results of the tests suggested that CMI was weak then the subject received a booster shot of the vaccine (to a maximum of 6 boosters). Researchers monitored subjects for up to 2 years. They have just released data on the results of the first 9 months.

* RESULTS

At the beginning of the study subjects had various levels of CMI. Over time, subjects who received the vaccine had higher and sustained levels of CMI against H1V compared to subjects who received IFA. For each dose of the vaccine this effect was statistically significant. It appeared that the 100 mcg dose was "as effective as the 400 mcg dose in [boosting CMI against HIV] over the course of the study."

Based on these preliminary and promising results, the Immune Response Corporation is planning larger studies.

REFERENCES:

1. Turner JL, Trauger RJ, Daigle AE and Carlo DJ. HIV-1 Immunogen induction of HIV-1-specific delayed-type hypersensitivity: results of a double-blind, adjuvant- controlled, dose-ranging trial. AIDS 1994;8(10):1429-1435.

950301
CATE5710

Copyright © 1995 - TreatmentUpdate. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Editor, The Canadian AIDS Treatment Information Exchange, 555 Richmond St. West, Suite 505, Box 1104, Toronto, ON, M5V 3B1 • Phone: 416-203-7122 • Toll Free: 1-800-263-1638 • Fax: 416-203-8284  http://www.catie.ca